Investing.com – U.S. equities were lower at the close on Friday, as losses in the Basic Materials, Utilities and Technology sectors propelled shares lower. At the close in NYSE,...
Amgen Inc (NASDAQ: AMGN) announced data from a Phase 1b/2 study evaluating the combination of Lumakras (sotorasib) with Vectibix (panitumumab) in patients with KRAS G12C-mutated...
Amgen (AMGN) announces the first combination study results from Phase 1b/2 CodeBreaK 101 study in patients with KRAS G12C-mutated advanced colorectal cancer ((CRC)).These new data...
A deep dive look at Amgen, its valuation, its future prospects, and the quality and strength of its financial statement.
Biotech giant Amgen (AMGN) reported fairly tepid second-quarter 2021 results on Tuesday (August 3). While the company surpassed the consensus estimates for both top line and...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Buy | Sell | Neutral |
| Technical Indicators | Buy | Strong Buy | Strong Buy | Strong Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 0.25 | 0.00 | 0.00 | -0.0300 | -10.71% | 539.00K | Toronto | |||
| 136.03 | 142.40 | 136.00 | -4.62 | -3.29% | 65.28K | TSXV | |||
| 1.41 | 1.44 | 1.35 | -0.03 | -2.08% | 1.04M | Toronto | |||
| 171.78 | 180.00 | 170.50 | -3.26 | -1.86% | 3.02M | Toronto | |||
| 0.062 | 0.00 | 0.00 | +0.003 | +4.17% | 2.60M | Toronto | |||
| 28.72 | 28.77 | 28.51 | -0.04 | -0.14% | 6.81M | Toronto | |||
| 0.77 | 0.00 | 0.00 | 0.000 | 0.00% | 2.39K | Toronto | |||
| 0.50 | 0.00 | 0.00 | 0.000 | 0.00% | 6.02K | Toronto | |||
| 2.23 | 2.24 | 2.16 | +0.01 | +0.45% | 67.38K | Toronto | |||
| 0.095 | 0.00 | 0.00 | 0.000 | 0.00% | 0.00 | CSE | |||
| 23.02 | 23.23 | 22.62 | -0.08 | -0.35% | 2.56M | Toronto | |||
| 7.35 | 7.36 | 7.34 | +0.01 | +0.14% | 4.44K | TSXV | |||
| 0.09 | 0.00 | 0.00 | 0.0000 | 0.00% | 183.65K | TSXV | |||
| 0.54 | 0.00 | 0.00 | +0.105 | +24.14% | 1.37M | CSE | |||
| 30.09 | 30.54 | 29.37 | +0.92 | +3.15% | 1.45M | Toronto |
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.